10-K · March 12, 2026
BeautyHealth (SKIN) reports Q4 revenue of $82,400,000 (beat consensus $78,138,140) and GAAP diluted EPS of $(0.06) (in line with estimate). Full-year revenue declined to $301,000,000 in 2025 from $334,000,000 in 2024,…
Earnings analysis · 10-Q
SKIN earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
SkinHealth Systems reported Q1 2026 results with revenue of $64.9 million, down from $69.6 million in Q1 2025, reflecting a 6.7% year-over-year decline. Diluted EPS improved to -$0.05 from -$0.08 a year prior, showing a…
Read full summary
SkinHealth Systems reported Q1 2026 results with revenue of $64.9 million, down from $69.6 million in Q1 2025, reflecting a 6.7% year-over-year decline. Diluted EPS improved to -$0.05 from -$0.08 a year prior, showing a positive trend despite missing revenue expectations by 2.1%.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.05
- Gross margin
- 68.5%
- Segment
- Delivery Systems: $18.5M; Consumables: $46.4M
What stood out
-
Revenue Decline Year-Over-Year
Revenue decreased to $64.9 million from $69.6 million, a decline of 6.7% compared to Q1 2025.
-
Better EPS Performance Than Expected
Diluted EPS improved to -$0.05 from -$0.08 year-over-year, exceeding estimates of -$0.08.
-
Reduced Operating Expenses
Total operating expenses for Q1 2026 were $46.2 million, down from $60.6 million in Q1 2025, a decrease of 23.8%.
-
Higher Gross Margin Relative to Sales
Gross profit was $44.4 million with a gross margin of 68.5%, down slightly from 69.8% a year prior.
-
Post-Repurchase Cash Position
Cash, cash equivalents, and restricted cash decreased to $204.4 million, down from $232.7 million at the beginning of the quarter.
-
Management Expresses Commitment to Operational Improvements
Management has highlighted efforts to optimize product costs alongside facing macroeconomic challenges.
What to watch
-
Sales Decline in Delivery Systems and Consumables
Delivery Systems revenue dropped by 8.3% and Consumables by 6.1% year-over-year, affecting overall financial performance.
-
Increased Interest Expense
Interest expense surged to $6.3 million from $2.5 million, an increase of 154% compared to Q1 2025.
-
Pressure from Macroeconomic Factors
Management noted ongoing global economic conditions negatively impacting sales and customer spending.
Management's outlook
2026 revenue guidance reflects continued pressure on device sales.
Earlier filings 4
10-Q · November 6, 2025
The Beauty Health Company reported Q3 net sales of $70,655 (in thousands) and GAAP diluted loss per share of $(0.09). Gross profit expanded to $45,634 (64.6% gross margin) and operating loss narrowed to $(6,242) versus…
10-K · March 12, 2025
The 10-K frames The Beauty Health Company as a ‘‘medtech meets beauty’’ platform centered on Hydrafacial’s Syndeo Delivery System and a razor/razor‑blade consumables model, with an esthetician-focused go‑to‑market and…
10-Q · November 12, 2024
HydraFacial reported Q3 net sales of $78,802,000 and diluted EPS of $(0.15). Gross profit improved to $40,649,000 (51.6% margin) driven by a recovery in consumables, while the company remained unprofitable at the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.